News
Here’s What Ophthalmologists are Buying for Their Kids This Holiday Season
Ophthalmologists have long...
Are you ready for AAO 2022?
AAO 2022: Gather Where all...
Parents: Here are 5 Steps to Protect Your Young Athletes’ Eyes
Nearly 30,000 people suffer...
AAO Update: Upneeq™ (oxymetazoline hydrochloride ophthalmic solution 0.1%)
Upneeq™ (oxymetazoline hydrochloride ophthalmic solution 0.1%) is an ophthalmic drop which has acquired ptosis as an indication for its use. In response to concerns regarding the use of the drug by practitioners who may not be familiar with potentially serious neurological and orbital conditions associated with ptosis, the Academy, the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS), and the North American Neuro-Ophthalmology Society (NANOS) engaged with the Food and Drug Administration (FDA) to update the package insert for the product. The FDA has informed us that they agreed with our concerns and have approved an updated package insert that adds a new warning.
You can find the updated package insert here: http://pull.xmr3.com/p/10-CB41/93404408/UPNEEQ_New_Package_Insert.pdf
Ophthalmologists Urge Eye Protection for Recreational and Professional Sports
Ophthalmologists Urge Eye...
Sixty Percent of Americans with Diabetes Skip Annual Sight-Saving Exams
Sixty Percent of Americans...
AAO 2020 Is Going Virtual
The Academy's annual meeting...
AAO 2020 Vision
Learn More
Milestones and Vision Presentation
Click on the link below to...